The cluster of open-market sales by four senior executives without a disclosed 10b5-1 plan is a bearish signal. Monitor for upcoming clinical data readouts or financing events that may have prompted the selling. The next catalyst is likely the Phase 2 data for ziftomenib in AML, which could drive volatility.
Price Chart
Executive Summary
Four Kura Oncology insiders, including the CSO, COO, CMO, and SVP of Finance, sold a total of ~$476K in open-market shares over a one-week period. The CSO's sale followed a derivative exercise, and the cluster is concentrated among senior executives, which raises cautionary signals despite the modest absolute dollar amount relative to the company's market cap.
Key Financial Metrics
Key Facts
- Four insiders sold shares in open-market transactions between September 24 and September 28, 2026.
- Total open-market sales value: ~$476,000.
- CSO Francis Burrows sold 20,726 shares at $10.83, after exercising 60,000 options (30,000 at $6.15 and 30,000 at $0).
- COO Kathleen Ford sold 6,900 shares at $10.50.
- CMO Mollie Leoni sold 12,400 shares at $10.50.
- SVP Thomas James Doyle sold 4,600 shares at $10.50.
- All sales were open-market (code S) with no 10b5-1 plan indicated in the provided data.
- The cluster is concentrated among C-suite executives (CSO, COO, CMO) plus a senior finance officer.
Financial Impact
Total insider sales of ~$476K represent approximately 0.15% of KURA's market cap (~$326M based on ~$10.50 share price and ~31M shares outstanding).
Risk Factors
- Insider selling may signal management's lack of confidence in near-term prospects or upcoming negative catalysts.
- The CSO's sale following option exercise could be interpreted as portfolio diversification, but the cluster nature amplifies concern.
- KURA is a clinical-stage biotech with no approved products; any negative data readout could significantly impact the stock.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KURA-1790721043317 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 26d ago | Insider Cluster | $10.71 | awaiting T+60 | — | $9.67 (+9.71%) |
Sep 29, 2026 27d ago | Press Release | $10.81 | awaiting T+60 | — | $9.67 (−10.50%) |
Sep 9, 2026 6w ago | 8-K | $12.09 | awaiting T+60 | — | $9.67 (−20.02%) |
Sep 8, 2026 6w ago | 8-K | $12.52 | awaiting T+60 | — | $9.67 (−22.76%) |
Aug 24, 2026 8w ago | Insider Cluster | $13.59 | awaiting T+60 | — | $9.67 (−28.84%) |
Aug 21, 2026 9w ago | Insider Cluster | $12.40 | awaiting T+60 | — | $9.67 (−22.02%) |
Aug 17, 2026 9w ago | Insider Buy | $12.33 | awaiting T+60 | — | $9.67 (−21.57%) |
Aug 12, 2026 10w ago | Press Release | $10.09 | awaiting T+60 | — | $9.67 (−4.16%) |
Aug 5, 2026 11w ago | Press Release | $9.20 | awaiting T+60 | — | $9.67 (+5.11%) |
Jul 29, 2026 12w ago | 8-K | $9.31 $9.61 | ▲ +3.22% | ▲ +0.76% | $9.67 (+3.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers